Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/49213
WHOLE BLOOD MRNA EXPRESSION‑BASED TARGETS TO DISCRIMINATE ACTIVE TUBERCULOSIS FROM LATENT INFECTION AND OTHER PULMONARY DISEASES
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Barretos Cancer Hospital. Molecular Oncology Research Center. Barretos, SP, Brazil.
Barretos Cancer Hospital. Molecular Oncology Research Center. Barretos, SP, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Barretos Cancer Hospital. Molecular Oncology Research Center. Barretos, SP, Brazil / Medical School, University of Minho. Life and Health Sciences Research Institute. Braga, Portugal. / Government Associate Laboratory. Braga, Guimarães, Portugal.
Fundação José Silveira. Salvador, BA, Brazil.
University of California. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, USA.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Barretos Cancer Hospital. Molecular Oncology Research Center. Barretos, SP, Brazil.
Barretos Cancer Hospital. Molecular Oncology Research Center. Barretos, SP, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Barretos Cancer Hospital. Molecular Oncology Research Center. Barretos, SP, Brazil / Medical School, University of Minho. Life and Health Sciences Research Institute. Braga, Portugal. / Government Associate Laboratory. Braga, Guimarães, Portugal.
Fundação José Silveira. Salvador, BA, Brazil.
University of California. School of Public Health. Division of Infectious Diseases and Vaccinology. Berkeley, USA.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado em Saúde Pública. Salvador, BA, Brasil.
Abstract
Current diagnostic tests for tuberculosis (TB) are not able to predict reactivation disease progression
from latent TB infection (LTBI). The main barrier to predicting reactivation disease is the lack of our
understanding of host biomarkers associated with progression from latent infection to active disease.
Here, we applied an immune-based gene expression profile by NanoString platform to identify
whole blood markers that can distinguish active TB from other lung diseases (OPD), and that could
be further evaluated as a reactivation TB predictor. Among 23 candidate genes that differentiated
patients with active TB from those with OPD, nine genes (CD274, CEACAM1, CR1, FCGR1A/B, IFITM1,
IRAK3, LILRA6, MAPK14, PDCD1LG2) demonstrated sensitivity and specificity of 100%. Seven genes
(C1QB, C2, CCR2, CCRL2, LILRB4, MAPK14, MSR1) distinguished TB from LTBI with sensitivity and
specificity between 82 and 100%. This study identified single gene candidates that distinguished TB
from OPD and LTBI with high sensitivity and specificity (both > 82%), which may be further evaluated
as diagnostic for disease and as predictive markers for reactivation TB.
Share